The objective of this study was to investigate the effects on outcomes and morbidity of combining temp eraturecontrolled radiofrequ ency (TCRF) tongu e reduction with uvulopalatopharyngoplas ty (UP?P) as an initial sitedirected approach to the surgical treatm ent ofobstructiv e sleep apn ea syndrome (OSAS) . This investigation was a p rospecti ve, nonrandomized, ope n-enrollment study of 20 consecutive eligible patient s with OSAS. Seven patients had a single-level velopharyngeal obstruction (Fujita type l or IIa ), and they were assig ned to undergo UPPP only (g roup I ). Th irteen patients had a multilevel velophary ngeal and retroglossal obstruction (Fuj ita type IIb), and they were ass igned to undergo TCRF tongue reduction in addition to UPP? (gro up 2). Pati ents who had only a retroglossal obstruction (Fujita type III) were not included in this study. Following their initial operation, nin e patients in group 2 underwent two subsequent in-office TCRF tongu e treatm ents under local anesthesia . Three patients in group 2 were lost to followup, and one pati ent underwent only one TCRF procedure at the initial operation; data on the latter patient are included in som e of the outc omes measu res repo rted here where indicated, but no data are report ed on the three who were lost to fo llowup. The primary post-treatm ent outcomes mea sures were the results of comparative polysomn ography and clini cian and patient evaluations regarding morbidity and symptom improvement. Analysis of these data showed that there was no difference between the two groups in terms ofpostoperative pain or dyspha gia f ol-Dr. Nelson is an otolaryngo logist-head and neck surgeon in priva te practice in San Jose, Calif. Reprint req uests: Lionel M. Nelson, MD, lowing the initial operativ e session . The degree ofsymptom improvement in the two groups was similar. Overall success rates-as measured by the apn ea/ltypopn ea index (group I: 57.1 % success; group 2: 50.0%) and by the apnea index (group I: 71.4% success; gro up 2: 70.0% )were statistically comparable, given the small size of the sample (fig ures are based on IO patients in group 2) . The auth or concludes that combining TCRF tongue reduction with UPPP in patients with multilevel obstruction improves respons e rates to a degree that is comparable to that seen with UPPP alone in patients with sing lelevel velophary ngeal obstruction. Moreover, the comb ination treatm ent does not increase the risk ofadditional pain, morbidity, and complica tions compared with UP?P alone.
Introduction
Over the past 2 decades, uvulopalatopharyngoplasty (UPPP) has become one of the more frequently used surgical trea tments for obstructive sleep apnea syndrome (OSAS). Its relative technical simplicity and the usually uncomplicated postoperative course have made it a popular option for most otol aryngologists . However, despite encouraging reports by patients of subjective qual ity-oflife improvements, outcomes have been disappo inting. Amon g patients with retropalatal narrowin g or collapse (Fujita type I or IIa obstruction), the clin ical respon se to Uppp (as defined by a reduction in the apnea/hypopnea index [AHI] of~50 % and a post-treatment AHI of <20 in patients whose AHI was >20 preoperati vely) has been reported to be 52.3 %.1But for patient s with a retrolingual narro wing or collapse, with or without a retropalatal component (Fuj ita type IIb or III obstruction), the UPPP response rate is only 5.3 %.1Although the Fujita clas sification system is an oversimplified representation of airway compromise in OSAS , it does indicate the presence of obstruction at multilevel sites , each of which must be addre ssed surgically.
Several approaches have been advocated to improve the low UPPP response rate among patients with Fujita Sixty pediatric patients2 to 5 years of age received 5 mg loratadine once daily in a double-blind, placebocont rolled clinical trial for aperiod of14da ys. No unexpected adverse events wereseen given theknown safet y profileof loratadine and likely adverse reactions for this patient population. The following adverse events occu rred with a lrequency ot 2 to 3 percent in the loratadine syrup-treated patients (2 to 5 years old)during the placebo -controlled trial. and more frequently than in the placebo group: diarrhea . epi staxis. pharyngitis. influenza-likesymptoms, fatigue. stomatitis. tooth disorder, earache, viral infection,and rash .
In additIOn tothoseadverse events reported above (~2 ' 10) , thefollowing adverse eventshave been reported inaueast one patient inCLARI TI Nclinical trials inadult and pediatricpatients: In addition. the following spontaneou s adverse events havebeen reported rarely during fhe markelingof loratadine: abnormal hepaticfunction, including [aundice. hepatitis, and hepaticnecrosi s:alopecia: anaphylaxis: breast enlargement: erythema multiforme:peripheral edema; thrombocytopenia: andseizures. OVEROOSAGE In adults. somnolence, tachycardia. and headache have been reported with overdoses greater than 10mg withthe Tabl et lorrnulation (40 mg-180 mg). Extrapyramidal signsandpalpitations have been repo rted in children with overdoses of greater than 10 mg ot CLAR ITIN Syrup. In the eve nt of overdosage. general symptoma tic and suppo rtive measures shoul d be instituted promp tly and maintained foras longas necessary.
Treatment ofoverdosage would reasonablyconsist of emesis(ipecac syrup) , except inpatents with impaired consciousness. followed bythe administration ofactivated charcoa l to absorb anyremaining drug. II vomiting is unsuccessful, or conlra indicated. gastriclavage should be performed wit h normal sa line. Saline catha rtics ma y also be of value for rapid dilution of bowel conte nts. Loratadine is not eliminated byhemodialysis. II isnot known if loratadine isel iminated byperitoneal dialysis.
No deaths occu rred at oraldoses up 10 5000 mglkg in mice (approximately 1200 and 1400 times. respectively, themaximum recommended daily oral dose inadultsand children ona mg/m' basis).No deaths occu rred at oral doses up to 5000 mglkg in matured rats (approximalely 2400 and 2900 times, respectively. themaximum recommended daily oral dose inadulls and childrenonamglm' basis). However, lethalily occurred in juveni le rats atan oral dose of 125 mglkg (approximal ely 100 and70times. respeclively, the maximum recommended daily oral dose inadultsand children ona mglm' basis). No deaths occurred atoral doses upto 1280 mglkgin monkeys (approxi mately 2100 and t500 times, respectively, the maximum recommended daily oral dose inadultsand children onamglm' basis). Admini stration of CLAR ITINRED ITABS (Ioratadine rap idly-dis integrating tablets) did not resu lt in an increased reporting trequency of mouthortongueirritation.
Ner vousness
CLARITI NSyrup : Approximately 300 pediatric palients 6 to 12 years of age received 10mg loratadine once daily incontrolled clinical trials foraperiod of8to 15days. Among these. 188 children were treated with 10mg loratadine syrup once daily in placebo-controlled trials. Adverse events in these pedia tric patients were observed tooccur withtypeand frequency similartothoseseen intheadult pop ulation. The rateof premature di sconti nuanceduetoadverse eve ntsamong pediatricpatients receiving lorataome10mgdailywas less Ihan t%.
CLARITIN® brand of loratadine

TABLETS , SYRUP, and RAPIDLY-DISINTEGRATING TABLETS
Adverse eventsreported inplacebo-controlled chronicidi opat hi curticaria trialsweresimilartothose reported inallergic rhinitisstudies.
Adverse event rates did nolappear to differ signifICantly based on age. sex. orrace. allhoughthe numb erof nonwhiteSUbjectswasrelativelysmall. Orug Interactio ns: Lor atadme (10 mg once dai ly) has been coad ministered wi th therapeutic doses of erythromycin. cimetidine. and ketoconazo'e in controlled clinical pharmacology stucies in adul t volunteer s. Although increased plasma concentrat ions (AUC 0·24 hrs)of loratad ineandlor descarboethoxyloratadme were observed foll owingcoadministrationolloratad ine witheach ofthese drugs innormal volunteers (ne 24 ineach sludy). ther ewerenocl imcally releva ntchanges inthe safet y profile ofloratadine. as assessed by electrocardiographic para meters. cl inical laboratory tests.vital signs. and adverse events. Therewere nosignificant effects onOTcint erval s.and noreportsot sedationor syncope. No effects on plasma concentrations ot cimetidine or ketoconazole were obse rved . Plasma concentrations (AUC 0-24 hrs) of erythromycindecreased 15% wi th coadministration ol loratadine relativetothatobserved l'lith erythromycin alone. The cli nical relevance of this difference isunknown. These above Iindmgsaresummarized inthe loll owi ngtable:
LORATAOI
Effects 
+73%
There does notappear tobe an increase inadverse eventsinS Ubjects who received oral contraceplives and loratadine.
Carc inogenesis, Mutage nesis, andImp airment ot Fertility: In ant s-menm carcinogenicity study in mice anda2-year study in rats, loratadinewas administered inthe di et atdoses upto40mglkg (miceI and25mglkg (rats). Inthe carcinogenicity studies. pharmacokinelicassessments werecarried outtodetermine animal exposure to the drug. AUC data demonstrated that the exposure of mice given 40 mglkg of loratadinewas 3.6 (Ioratadi ne)and 18 (descarboethoxyloraladi ne) limes the exposure in adults and5 (Ioraladine) and 20 Idescarboethoxyloratadinellimes the expos ure in children gi ven the maximum recommended dail y oral dose. Exposure ofrats gi ven 25mglkgofloratadine was28(Ioratadi ne)and 67(descarboethoxyloratadine) times Ihe exposure inadults and 40(Ioratadine) and 80(descarboethoxyloratadineltimesthe exposure inchildren given the max imumrecommended daily oral dose. Male mice given 40mglkg had asignilicantly higher incidence of hepatocellulartumors (combined adenomas and carcinomasi man concurrent controls. Inrats. a significantly higher inci dence01 hepatocellular tumors (combined adenomas and cardnomas) Vi as observed in males given 10mg/kg. and males and females gi ven 25mg/kg. Exposure of rats given 10 mglkg of loratadine was 10(lnratadine) and 15 (descarboethoxyloratadine) times the exposure in adul ts and 15(Ioratadine) and 20 (descarboethoxyloratadine) times the exposure in children given the maximum recommended daily oral dose. The cl inical significance ofthesefindings dur ing long-term use ofCLARITIN isnot known.
Inmutagenicity sfudies, ther ewas noevidence ofmutagenic polentialinreverse (Amesl orforward pointmutation (CHO-HGPRTIassays, orinthe assay forDNA damage(rat primary hepatocyte unscheduled DNA assay) orin twoassays lorchromosomal aberrations(humanper ipheral blood lymphocyte clastogenesisassay andIhemouse bone marrow erythrocyte micronucleus assay). In the mouselymphoma assay. apOSiti ve finding occurred in the nonactivated but not the activated phase ofthestudy.
Decreased fertil ity in male rats, shown by lower female concep tion rates . occu rred at anoral dose of 64 mglkg(approximately 50times Ihe maximum recommended human daily oral dose onamglm' basis) and Vias reversible with cessation ot dosing. Loratadi nehad noeffect onmale or female fertilityorreproduction in therat at anoral dose ofapproximately 24mglkg(approximatel y 20times the maximumrecommended human dailyoral dose onamglm' basis).
Pregnancy Ca tegory B: Therewas noevidence ofanimal teratogenicity instudies perlormed in rats and rabbi tsatoral doses upto 96mglkg(approximately 75 limes and 150 times. respectively, themaximum recommended humandaily oral dose onamglm' basis). There are. however, noadeq uate and well-controlled studies in pregnant women. Because animal reproductionstudies are notalways predictive of human response. CLARITIN should be used dur ing pregnancyonly if clearly needed.
Nursing Mothers: Loratadineand its metabolite, descarboethoxyloratadine. pass easily into breast mi lk and achieve concentrations that are equivalent toplasma level s withanAUC m il k/AUCpl,.,,, ratio of1. 17and 0.85 for loratadineand descarboethoxyloratadine. respectively. Following asingleoral doseof40mg. asmall amount of loratadine and descarboethoxyloratad ine was excreted intothebreast mi lk(approximately 0.03%of40mg over 48hours) . A decision shoul d be made whether to discontinue nursing or todiscontinue the drug, tak ing into account theimportanceofthe drug tothe mother. Caution should be exercised when CLARITINis administered toanursingwoman.
Pediatric Use : The safety of CLARITIN Syrup at a daily dose of 10 mghas been demonstrated in 188 pediatric patients 6 to 12years of age in placebo-controlled 2-week trials. The safety and toler ability of CLARITIN Syrup atadailydose of 5 mg has been demonstrafed in 60pediatric panents 2to5years01 age ina double-blind. placebo-controlled. 2-week study. The effectiveness of CLARITINforthe treatment of seasonal allergic rhinifisand chronic idiopathic urt icaria inchi ldren aged 2to 12years is based onan extrapolation ofIhe oemonstrated efficacy of CLARITIN in adults in these conditionsand Ihe likelihood that the disease course, pathophysiology. andthe drug's effect are substantially similartothat otthe adults. Therecommended dose for thepediatricpopulation isbasedoncross-studycomparison ofthepharmacokinetics ofCLARITINinadults and pediatric subjects and on the safety profileof loratadinein bothadul tsandpediatricpatients at doses equal to orhigherthan the recommended doses.The safel y and effecliveness of CLARITIN inchildren under 2year s of age have not been established. ADVERSE REACTION S CLARITINTablets: App roximately 90,000 patien ts, aged 12and older. received CLARITIN Tablets 10mg once daily incontrolled and uncontrolled studies. Placebo-controlled clinical trials at therecommended doseof 10mg once aday variedfrom 2weeks' to6months' duration. The rate ofpremature withdrawalfromthese trials was approximately2%inboththe treated and placebogroups.
REPORTED ADVERSE EVENTS WI TH ANINCIOENCE OF MORE THAN2%INPLACEBO-CONTROLLED ALLERGIC RHI NITIS CLINICAL TRI ALSINPATIENTS 12YEARS OF AGE AND OLD ER PERC ENTOF PATIENTS REPORTING
type lIb ob struction, who make up the largest group of OSAS patients. They include limited tongue resection, midline glossectorny/epiglottidectomy, lingualplasty, genioglossal ad vancement, and hyoid myotomy with suspension.' Yet most otolaryngologists are reluctant to undertake the se additional, highly inva sive procedures. Their reasons include a lack of confidence that such a procedure will be successful , a fear of complications and increased morbidity, and the need for a high degree of technical expertise.' One procedure that has been shown to be safe, effective, we ll tolerated , and technically straightforward in red ucing retroglossal obstruction and co llapse is tem peraturecontro lled radiofrequency (TCRF) tongue re duction (Sornnoplasty"). In a study of 18 patients who underwent TCRF tongue reduction, Powell et al reported a mean decrease of 17% in tongue volume following an average delivery of 8,490 J to the base of the tongue." T he procedure lowered the me an respiratory disturbance index from 39 .6 to 17.8 and raised the mean Sa0 2 nadir from 81.9 to 88.3 %.
The technical simplicity and relative tolerability of TCRF tongue reduction could make it an appealing option for practitioners and for patients with multilevel obstruction as an initial site-directed operation in combination with UP PP . If this combination ultimately pro ves to be successful and increases the percentage of successful init ial responders, it would decrease the size of the patient population that req uires a graduated treatment plan and more-invasive operations.
T he present feasibility study was undertaken to investigate this co nce pt. Its goal was answer two questions:
• Does the addition ofTCRF tongue reduction to UPPP add to the risk of adverse effe cts or to the degree of discomfort?
• Will the combination increase the treatment success rate in patients with multilevel retropalatal and retroglossal obstruction to a level that is comparable to that achieved by UPPP alone in patients with single-level retropalatal obstruction ?
Pat ients and methods
The present investigation was a prospective, nonrandornized, open-enrollment study of 20 con secutive patients who were seen at the author's community-based general otolaryngology practice. Eligible patients had polysomnographically documented OSAS, were seeking a surgical treatment option, and met the inclusion criteria established by an institutional review board-approved protocol. Inclusion was not restricted by the severity of OSAS or by the patient' s weight, age, or sex .
Based on physical examination with supine pharyngoscopy an d cephalometric x-ray imag ing, the study Volume 80, Number 9 population was divided into two groups. Se ven patients (mean age: 35 .8 yr; mean bod y-mass index [BMI]: 32.3; six men ) had primarily sing le-level velopharyngeal obstruction (Fujita type I or IIa), and they were designated as group 1. Thirteen patients (me an age : 51 .5 yr; mean BMI: 27.9; 12 men) had multilevel velopharyngeal and retroglossal obstruction (Fujita type Ilb), and they were designated as gro up 2. Patients who had only retroglossa l obstruction (Fujita type III) were not included in this study.
The criteria used to defi ne a significant retroglossal obstruction incl uded (1) an ina bility on the part of the surgeon to visual ize no more tha n the ary tenoi ds because of tongue enlargement during unforced end-expiration on supine pharyngoscopy wit h the endoscope in the oropharynx' and (2) the presence of a posterior airway space of 10 mm or less on end -expiration cephalometric x-ray analysis." Over the course of the study, three patients in group 2 were lost to followup.
Treatment consisted of an initial operative procedure under general anesthesia in which all pat ients underwent trad itional surgical UPPP, along with removal of the tonsils (if present), septoplasty (if indicated), and turbinate reduction (either surgical submucosal resection or TCRF tounge reduction, depending on the type of turbinate obstruction). In addition, patients in group 2 underwe nt their first TCR F tongue-reduction procedure during that initial operative session. All patients were hospitalized overnight.
Su bsequently, nine of the 10 remaining pat ients in gro up 2 underwent two additional in-office TC RF tongue reductions under local anesthesia; these repeat TCR F tong ue-reduction procedures were spaced 3 to 6 weeks apart. (The remaining pa tient underwent only the ini tia l TC RF procedure [4,000 J] and required no further treatment; the data on this patient are included in some outcomes measures where indicated .) During all TC RF procedures, two to six submuco sal lesions per session were cre ated by delivering 1,000 J of energy to eac h site at 85°C with an S2 control unit (set to the maximum power setting of 10 W) and a commercially available model 1200 tongue handpiece (Somnus Medical Technologies; Sunnyvale , Calif.). Each of the nine patients received a cumulative dose of approximately 12,000 J.
Initial followup examinations and questionnaires were administered 1 to 3 days following each phase of treatment, and again at 1,4, and 8 weeks . The questionnaires gathered information on treatment morbidity and the status of OS AS symptoms. Responses were quantified by using the Epworth sleepiness scale and visual analog scales for day time sleepiness, snoring, dysphonia, dysphagia, and throat pain (as sessments of pai n in ge neral as we ll as pain that was perceived to be localized to the 
N/A N/A
Group 2 (n = 9)
6.9 ± 2.2 3.1 ± 3.1 4.0 ± 2.9 1.9 ± 2.6 0.5 ± 1.1 palate, nose, and tongue). Attended sleep studies were repeated 2 months follow ing the completion of all treatment.
Results
There were no clinica lly significant complica tions in either gro up. Neither gro up experie nced hemorrhage, clinically sign ificant infections, or respiratory problem s, and no patient required hospitalization beyond the initi al posto perative short stay. The two gro ups exhibited similar degrees of temporary nasa l congestion, which is typical followi ng nasal procedures, as well as initial oro pharyngeal pai n and dysphagia.
Subjective assessments of outcome. Following the initial operative sess ion, there was generally no sig nificant difference between the two gro ups in the degree of postoperative discomfort (table) . The one exce ptio n was that gro up 2 experienced more palatal pain at postoperative week I, although not before or after. The subseq uent in-office TCRF tongue reductio ns administered to the nine patients in group 2 under local anesthesia were well tolerated, and most of them were able to return to normal activity within 24 hour s (table) . All of these patients experie nced mild tongue edema and pain I to 3 days follow ing their additional treat ments, but these disturb ances resolved within I week.
All patient s in both gro ups, including the one patient in gro up 2 who underwent only one TCRF proced ure, reported subjective improve ment in their OSAS sympto ms (figure) . Th e difference in improvement between the two groups was not statistically significant, give n the small sample size . 642 Apnea/liypopnea index. Objective assess ments of response were based on indivi dual AHI and apnea index (AI) values. A successful response in ter ms of AHI was defined as a redu ction of at least 50% in AHI and the attainment of a post-treatment AHI ofless than 20 in those patients whose preoperative AHI was greater than 20.
As determined by the AHI, success rates in the two groups were co mparable; four of the seven patients in gro up I (57. 1%) and five of the lOin group 2 (50.0%) were conside red to have experienced a successful response to therapy . The mean AHI values in group I fell from 47.2 (±29. 1) before treatment to 20.5 (±23 .6) afte rward; the corresponding decline in gro up 2 was from 29.5 (± 14.8) to 18.8 (± 14.6). The difference between the two groups in the mean post-treatment AHI was not statistically significa nt. The difference between the mean preand post-treatm ent AHI values approached statistical significance in both gro ups (p =0.07).
Apn ea index. Although efforts were made to use the same sleep fac ility for pre-and postoperative testing for each patient, this was not possible for two of the 17 patients. Th is is noteworthy because hypopneas can be score d differentl y by techni cians in different facilitiesand indeed eve n by individual techn icians within the same facility-which can skew the AHI value. Therefore, each patient was also evaluated acco rding to his or her AI value. A successful response to trea tment was defined as a reduction in AI of at least 50% and the attainment of a post-treatment AI of less than lOin those patients whose preoperative AI was grea ter than 10.
As determined by the AI, success rates in the two groups were comparable; five of the seve n patients in peared to improve success rates in patients with both velopharyngeal and retro glossal obstruc tion to levels that are compara ble to those achieved with UPPP alone in patients with single-leve l velophary ngeal obstruction.
TCRF tongue redu ction is techni cally straightforw ard, and it can be eas ily mastered by the practicing otolaryngologist with a minimum of additi onal instru ction . Mor eover, because patient s who undergo UPPP are routinely hospitalized, adding the TCRF procedure to UPPP provides maximal use of the hospital stay, and patient s can be observed for the occ urrence of any adverse effects that might influenc e the success or failure of any future inoffice treatment. Because it is minim ally invasive and well tolerated, TCRF tongue reduction might be an acceptable adjunct to already-planned surgery. Its use co uld enco urage patients and practitioners to undertake a more inclusive site-directed initial approac h to treatment. Ultimatel y, the addition of TCRF tongue reduction to UPPP could impro ve initi al response rates in the largest segment of the OSAS population-those with multil evel obstructions-and would decrease the size of the patient popul ation that requires more-costly and more-morbid interve ntions. 
Discussion
Thi s study was undertaken to test the feasi bility of a concept. Although the small numb er of patient s and the demograph ic varia nce between the two groups lim it both statistical significa nce and confidence bound aries in validatin g results, cer tain trends are ev iden t. Fore most among them is that the addition of TCRF tongue reduction to UPPP does not appea r to significa ntly increase the degree of pain and morbid ity or the incide nce of co mplicatio ns compared with UPPP alone. In this study popul ationwhich is fairly typical of a community-ba sed ge neral otol aryngolo gy practice-combining TCRF tongue reduction with UPPP as an initial operative appr oach ap-group I (71.4%) and seve n of the 10 patient s in group 2 (70.0%) were co nsidered to have experienced a successful response to ther apy. The mean AI value s in group I fell from 23.8 (±24.2) before treatm ent to 4.6 (±5.3) afterward; the corres ponding declin e in gro up 2 was fro m 8.7 (±6.4) to 3.7 (±4.9) . The difference between the two groups in the mean post-treatm ent AI was not statistically significant. The difference between the mean pre-and post-treatm en t AI was significa nt in group 2 (p =0.05), but not in group I, probably because of the small size of the sample. Figure. According to subjective analyses, symptoms decreased in both groups fo llow ing treatment. Mean scores are shown for the Epwor th sleep iness scale (scale: 0 to 24) and visual analog scales ( 1 to 10) for daytime sleepiness and snoring. The posttreatment diffe rences between the two groups were not significant. In group 1 (U PPP only), the differe nces between the preand post-treatm ent scores on the Epwo rth and daytime sleepiness scales were statistically significan t (p<0.05). In gro up 2 (combination UPPP and TCRF tongue reduction; n = 10), all differe nces between the pre-and post-treatment scores were statist ically significant.
